Crescendo Biologics and Takeda Enter Collaboration for Humabody®-based Therapeutics Worth up to $790m

Crescendo Biologics and Takeda Enter Collaboration for Humabody®-based Therapeutics Worth up to $790m
view PDF

Crescendo strengthens IP portfolio with U.S. patent

Crescendo strengthens IP portfolio with U.S. patent to transgenic mouse platform for generating Humabody® therapeutics.
view PDF

Crescendo Appoints New Chairman

Crescendo Appoints New Chairman
view PDF

Crescendo Biologics Expands ADC Programmes with Innovate UK Funding Award: Biomedical Catalyst Award to Support Development of New Therapies to Target Prostate Cancer

Crescendo Biologics Expands ADC Programmes with Innovate UK Funding Award: Biomedical Catalyst Award to Support Development of New Therapies to Target Prostate Cancer
view PDF

Crescendo Biologics’ Receives Further Investment from Astellas Venture Management to Develop Novel Humabody™ Therapeutics Targeting Immune Checkpoint Inhibitors

Crescendo Biologics’ Receives Further Investment from Astellas Venture Management to Develop Novel Humabody™ Therapeutics Targeting Immune Checkpoint Inhibitors
view PDF